Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial

• Authors: SALEK Cyril; FOLBER František; HRABOVSKÝ Štěpán; KORISTEK Zdenek; HORACEK Jan M; FRONKOVA Eva; SOUKUP Petr; BENKOVA Katerina; CETKOVSKY Petr; TRKA Jan; DOUBEK Michael
• Year of publication: 2022
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.